11.14.25 -- Partnering To Commercialize Radiopharmaceuticals

Financial pressures and unconfirmed efficacy are driving changes to France's EAP. Stricter evidence, RWE, and robust development plans will soon be required to secure early access for therapies.

An innovative educational outreach initiative has hit the road to spread awareness about clinical research and highlights the importance of diverse representation in clinical trials.

Explore the causes of high screen fail rates, their impact on patient recruitment for clinical trials, and how they disproportionately impact underrepresented demographics.

To ensure that your adeno-associated virus (AAV) therapy reaches patients as soon as possible, begin your relationship with an experienced AAV manufacturer early in the development journey.

By confronting misconceptions about community-based research, we uncover evidence of how sites effectively manage complex trials while maintaining high standards of care.

Unlock the potential of antibody-drug conjugates (ADCs) by exploring our novel payloads, designed for easy access and evaluation, to accelerate your ADC drug development with proven efficacy and safety.

Discover key themes surrounding payments to clinical research participants in depth, with a particular focus on the role of participant compensation and best practices in payment logistics.